Dear colleagues,

There is accumulating evidence that regulated cell death (RCD) plays an important role in shaping the tumor microenvironment (TME), affecting tumorigenesis and metastasis. Immunogenic effects of some cell death modalities like necroptosis, ferroptosis, pyroptosis, or PANoptosis are exploited in cancer treatment and considered a promising therapeutic target that is alternative to “immunologically silent” apoptosis. Induction of non-apoptotic RCDs is especially tempting in apoptosis-resistant tumors. Notably, non-apoptotic RCDs can be modulated in TME cells, which is a promising therapeutic avenue. In particular, necroptosis, which is a regulated pro-inflammatory, necrotic cell death associated with lytic morphology, is under investigation as a target in multiple tumors. Extensive crosstalk between apoptosis and necroptosis is widely documented with caspase-8 playing a role of the major switch between these two lethal subroutines.

This Special Issue focuses on investigating the interplay between “immunologically silent” apoptosis and strongly immunogenic necroptosis in lymphomas and its possible targeting in lymphoma therapy. Original articles, review papers, and meta-analyses providing insights into molecular factors mediating the interplay between apoptosis and necroptosis in lymphoma, molecular mechanisms involved in the regulation of the apoptotic and necroptotic machinery, apoptosis/necroptosis-focused therapeutic interventions, novel therapeutic targets linked to apoptotic or necroptotic pathways, immunogenic TME-modulating effects of apoptosis and necroptosis in lymphoma and other related topics are cordially welcomed.

Apoptosis

Caspases

Cell signaling

Necroptosis

Non-Hodgkin lymphoma

Regulated cell death

RIPK1